Hemi-synthesis of novel (S)-carvone hydrazone from Carum carvi L. essential oils: Structural and crystal characterization, targeted bioassays and molecular docking on human protein kinase (CK2) and Epidermal Growth factor Kinase (EGFK).

• A novel chiral (s)-carvone dihydrazone (s-CHD) was hemi-synthetized from the natural (s)-carvone by reacting oxalyldihydrazide (ODH) with caraway's seeds essential oil. • Enantio-pure (s)-carvone dihydrazone (s-CHD) is structurally characterized by Single-crystal X-ray diffraction, 2D-NMR spectroscopy and chiral LCMS analysis. • The (s)-CHD exhibited an antigrowth potential against HepG2, Hela, RAW 264.7 and MCF-7 tumor cell lines without affecting normal cells viability. • Molecular docking shows that (s)-CHD possesses high affinity towards the kinase domain receptors CK2 and EGFRk, being able to bind to the kinase ATP region. Polyfunctional N,O,O,N-type ligands such as the oxalyl dihydrazide (ODH) may induce formation of mono-, di-, and polynuclear complexes with natural monoterpene ketones, involving ligand bridging and Oxo-bridging. In this context, a novel chiral dihydrazone is designed through hemi-synthesis process by reacting oxalyldihydrazide (ODH) with (s)-carvone, the major compound of caraway's seeds essential oil. The C = N imine bi-condensation is performed without prior isolation of the natural (s)-carvone and the resulting (s)-carvone dihydrazone (s-CHD) is structurally characterized by Single-crystal X-ray diffraction, 2D-NMR spectroscopy and chiral LCMS analysis to confirm the formation of a single pure enantiomer. In -vitro cell-based assays were conducted on normal fibroblast (L929) using a presBlue (PB) fluorescence quantification method of cell-viability and by sulforhodamine B calorimetric cytotoxicity assays to determine the anti-proliferative effect on four human tumoral lines (NCI-H460, Hela, HepG2 and MCF-7) and normal PLP2. Anti-inflammatory assays were determined through NO production by Maurine LPS-stimulated macrophages (RAW 264.7). The (s)-CHD has no effect on normal cells viability (>88%) and PLP2 (GI50= 326 ug/mL), while a moderate (∼55%) to significant (∼63%) antigrowth potential was recorded against HepG2, Hela and MCF-7 tumor cell lines, where RAW 264.7 was feebly sensitive. A molecular docking was performed using Autodock vina software on the protein kinase CK2 and Epidermal Growth factor Kinase proteins EGFK and the dock scores allowed to identify significant binding affinities (lower ΔG and Ki values) and potential hydrophilic/hydrophobic interactions with (s)-CHD comparing to the clinical ellipticine as potential ligands. Molecular docking suggests that (s)-CHD possesses high affinity towards the kinase domain receptors CK2 and EGFR, being able to bind to the ATP region. [ABSTRACT FROM AUTHOR]